Log in to your Inderes Free account to see all free content on this page.
Genmab
1,793.50 DKK
+1.56 %
Less than 1K followers
GMAB
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Dividend
Investor consensus
+1.56 %
-14.47 %
-11.52 %
-11.34 %
+2.78 %
+9.69 %
-30.00 %
-11.30 %
+5,159.53 %
Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read moreMarket cap
115.23B DKK
Turnover
231.21M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
19.3.
2026
General meeting '26
7.5.
2026
Interim report Q1'26
6.8.
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Transactions in Connection with Share Buy-back Program
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio